Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancers-Reference-Cited by-同舟云学术

Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancers

Published:2008-02-14 Issue:4 Volume:29 Page:762-765
ISSN:0143-3334
Container-title:Carcinogenesis
language:en
Short-container-title:Carcinogenesis

Author:

Cybulski C.,Masojc B.,Oszutowska D.,Jaworowska E.,Grodzki T.,Waloszczyk P.,Serwatowski P.,Pankowski J.,Huzarski T.,Byrski T.,Gorski B.,Jakubowska A.,Debniak T.,Wokolorczyk D.,Gronwald J.,Tarnowska C.,Serrano-Fernandez P.,Lubinski J.,Narod S. A.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,General Medicine

Link

http://academic.oup.com/carcin/article-pdf/29/4/762/8196241/bgn044.pdf

Reference24 articles.

1. Association of two mutations in theCHEK2 gene with breast cancer

2. Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway

3. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations

4. CHEK2*1100delC and Susceptibility to Breast Cancer: A Collaborative Analysis Involving 10,860 Breast Cancer Cases and 9,065 Controls from 10 Studies

5. CHEK2 Is a Multiorgan Cancer Susceptibility Gene

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Protein-truncating and rare missense variants inATMandCHEK2and associations with cancer in UK Biobank whole-exome sequence data;Journal of Medical Genetics;2024-08-29

2. Protein-truncating and rare missense variants inATMandCHEK2and associations with cancer in UK Biobank whole-exome sequenced data;2024-07-03

3. Relationship between the Expression of CHK2 and p53 in Tumor Tissue and the Course of Papillary Thyroid Cancer in Patients with CHEK2 Germline Mutations;Cancers;2024-02-17

4. Management of individuals with germline pathogenic/likely pathogenic variants in CHEK2: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG);Genetics in Medicine;2023-10

5. Unleashing a Lazarus Effect With Selpercatinib in a Never-Smoker Patient With Stage IV, Chemo-Immunotherapy Refractory, RET C630Y-Mutant, Small-Cell Lung Cancer: A First Case Report;JCO Precision Oncology;2023-09